Compare Warner Music Group Corp (WMG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Warner Music Group Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Warner Music Group Corp trades at $25.06 (market cap $13.12B), while State Street SPDR S&P Biotech ETF trades at $159.44. The key difference: Warner Music Group Corp pays a 3.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Warner Music Group Corp nearer its low. Which is the better fit depends on your goals.
| WMG | XBI | |
|---|---|---|
Market Cap | $13.12B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $34.72 | $164.28 |
52-Week Low | $23.65 | $88.79 |
Enterprise Value | $17.42B | — |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Warner Music Group (WMG) trades at $24.78, down 6.17% in the past 24 hours, with a bearish technical signal and support near $23. Recent earnings show mixed results, with Q1 and Q2 2026 beats but Q3 and Q4 2025 misses. Revenue grew to $6.71B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, citing streaming growth and strategic renewals like the NetEase Cloud Music partnership announced July 16, 2026.
The outlook is cautiously optimistic, with strong analyst support and projected revenue growth to $7.3B in 2026. Risks include execution challenges amid leadership changes, competitive pressures, and market volatility. The current valuation at a P/E of 20.06 may appeal to growth-oriented investors, but near-term price weakness reflects earnings uncertainty.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
